
## Florent Grange

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8802162/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	WHO-EORTC classification for cutaneous lymphomas. Blood, 2005, 105, 3768-3785.	1.4	3,529
2	Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin. Journal of Clinical Oncology, 2011, 29, 3419-3426.	1.6	387
3	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2018, 19, 916-929.	10.7	131
4	Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome. The French Study Group on Cutaneous Lymphomas. Blood, 1999, 93, 3637-42.	1.4	77
5	Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis. Oncologist, 2016, 21, 76-83.	3.7	42
6	Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry*. British Journal of Dermatology, 2021, 184, 1059-1067.	1.5	39
7	Tâ€cell papulosis associated with Bâ€cell malignancy: a distinctive clinicopathologic entity. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1469-1475.	2.4	19
8	Pembrolizumab as first line therapy in patients with unresectable squamous cell carcinoma of the skin: Interim results of the phase 2 CARSKIN trial Journal of Clinical Oncology, 2018, 36, 9534-9534.	1.6	19
9	Safety and immunogenicity of MACE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature. ESMO Open, 2017, 2, e000203.	4.5	15
10	Cutaneous lymphomas appearing during treatment with biologics: 44 cases from theÂFrench Study Group on Cutaneous Lymphomas and French Pharmacovigilance Database. British Journal of Dermatology, 2019, 181, 616-618.	1.5	15
11	Efficacy and safety of panitumumab alone or in association with radiotherapy in unresectable cutaneous squamous cell carcinoma. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2789-2794.	2.4	9
12	Lymphomatoid papulosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: three cases. British Journal of Dermatology, 2018, 178, e5-e6.	1.5	6
13	Treatment of mycosis fungoides and Sézary syndrome with romidepsin: a series of 32 cases from the French Study Group for Cutaneous Lymphoma. British Journal of Dermatology, 2019, 180, 423-424.	1.5	5
14	KEYNOTE-629: Phase 2 study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma (cSCC) Journal of Clinical Oncology, 2019, 37, TPS9598-TPS9598.	1.6	5
15	Response to â€~Cutaneous eruptions associated with haematological malignancies: the need for a unifying nomenclature'. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e193-e193.	2.4	4
16	Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic. ESMO Open, 2018, 3, e000384.	4.5	1
17	Locoregional nodal extension does not impair prognosis of primary cutaneous anaplastic lymphomas. British Journal of Dermatology, 2021, 184, 356-358.	1.5	1